Fiorentino D, et al. Efficacy, safety, and target engagement of dazukibart, an IFN尾 specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2025 Jan 11;405(10473):137-146.聽